16 results about "Solid organ transplantation" patented technology

The invention provides a precise monitoring and self-adaptive regulation and control system for immunological rejection in solid organ transplantation. Relates to the field of artificial intelligence, and the system comprises a real-time data collection module which is used for collecting rejection-related biomarkers, organ function data and environment and treatment data in peripheral blood of a transplanted recipient in real time; the rejection risk prediction module is used for processing multi-dimensional time sequence characteristic data acquired in real time by adopting a long-short term memory network rejection risk prediction model based on layered boundary marginal loss function optimization, and outputting a rejection risk probability P; the intervention strategy generation module is used for generating an individualized intervention strategy through a mixed mask neighbor strategy optimization algorithm according to the current pathological state of the patient; and the intelligent decision regulation and control module is used for executing regulation and control decisions of precise regulation and control of the immunosuppressor and coordinated regulation and control of the organ microenvironment according to the rejection risk probability P and the individualized intervention strategy and performing real-time feedback. The rejection reaction recognition accuracy and intervention effectiveness are improved.

The present disclosure relates in some aspects to constructs and methods for increasing solid organ transplant survival. More specifically, aspects of the present disclosure relate to methods and constructs for administering full-length PD-L1 and one immune modulators, such as one or more of: CTLA-4, Qa-1d, HLA-E, HLA-G, CMTM6, and Indolamine-2,3-dioxygenase (IDO), by ex vivo perfusion in order to increase solid organ transplant survival.

The present invention relates to a product derived from allogeneically cultured postnatal thymus tissue for use in a method of inducing thymopoiesis and thereby promoting donor-specific tolerance to an allogeneic solid organ transplant in a recipient requiring a solid organ transplant, such as a heart, lung, liver, or other solid organ or part of a whole solid organ. The product derived from allogeneically cultured postnatal thymus tissue is prepared by subjecting suitable thymus tissue to a conditioning regimen, said conditioning regimen comprising the aseptic processing of the donor thymus tissue in a thymus organ medium and producing sections of donor thymus tissue partially devoid of T cells. The method of preparing the allogeneically cultured postnatal thymus tissue is further disclosed.

This invention provides a pharmaceutical composition for use in a method of preventing antibody-mediated rejection (ABMR) in subjects who have undergone solid organ transplantation by preventing complement activity. [Solution] A pharmaceutical composition comprising an anti-human interleukin-6 (IL-6) antibody or an anti-human IL-6 antibody fragment for use in a method of preventing, stabilizing, or reducing complement activity in a subject who is scheduled to receive, has received, or has received a solid organ transplant, wherein the method comprises administering to a subject a prophylactic or therapeutically effective amount of the antibody or antibody fragment, the pharmaceutical composition comprising a variable light chain polypeptide containing a CDR of a specific sequence, and a variable heavy chain polypeptide containing a CDR of a specific sequence.

B-cell maturation antigen (BCMA) is expressed on plasma cells. The present invention provides methods for desensitizing patients in need of a solid organ transplant to anti-HLA antibodies using bispecific antibodies that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing plasma cells. In certain embodiments, the bispecific antibodies of the present invention reduce alloantibody levels and / or reduce calculated panel reactive antibody levels to facilitate solid organ transplantation and / or improve long term graft survival and / or function.

The present invention relates to drugs, dosage regimens, dosing intervals, and methods of administration for treating antibody-mediated rejection using an effective amount of a drug targeting Blys and / or APRIL. The result shows that the provided effective dose of the drug targeting Blys and / or APRIL shows good safety and treatment effect in the process of preventing, treating or relieving antibody-mediated rejection in patients who are about to accept, are receiving or have accepted entity organ transplantation.

Described herein are methods, compositions, and systems useful for detecting transplant rejection and associated abnormal conditions in solid organ transplant recipients, such as pancreatic transplant recipients, pancreatic and kidney transplant recipients, and simultaneous pancreatic and kidney transplant recipients. Methods described herein may involve combined assessment of blood gene expression profiles from an assessment of particular, related mRNA transcript levels and donor-derived cell-free nucleic acids (dd-cfDNA) or each an independent assessment of the mRNA transcript level as well as an independent assessment of the dd-cfDNA. Genes that correlate with pancreatic transplant rejection in simultaneous pancreatic and kidney transplant recipients are also disclosed.

The invention features compositions and methods for treating transplant recipients (e.g., chronic allograft rejection) using a senolytic agent and an angiotensin II receptor antagonist or using a senolytic agent and senomorphic agent. The methods and compositions are useful in a variety of transplant settings including, without limitation, solid organ transplants including kidney, lung, heart, liver, intestine, or pancreas transplantation procedures and cellular transplants including but not limited to bone marrow transplants.

Provided herein are immunogenic polypeptides, compositions, and methods related to the development of CMV-specific prophylactic and / or therapeutic immunotherapies based on cytotoxic T cell (CTL)-recognized T cell epitopes (e.g., CMV epitopes), and can be used to prevent and / or treat CMV infection, reactivation, and / or disease (e.g., CMV-associated end-organ disease), especially in solid organ transplant recipients.

This invention describes new methods for the mobilization of human cells such as hematopoietic stem cells in bone marrow, and the subsequent collection of such cells from the peripheral blood of deceased donors. These methods produce quantities of hematopoietic stem cells that can be used in a multitude of possible applications without harming the deceased donor or the recovery of the deceased donor's organs for solid organ transplantation. The methods involve the administration of one or more mobilizing agents to mobilize bone marrow cells into the peripheral blood cells followed by the collection of cells via apheresis.

Provided herein are methods for the treatment or prevention of solid organ transplant rejection in a subject in need thereof, comprising administering to the subject a multispecific binding proteins comprising (a) a first antigen binding domain (ABD) comprising an immunoglobulin single variable domain (ISVD) (e.g., VHH) with binding specificity to CD28; and (b) a second ABD comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL) with binding specificity to OX40.

Provided herein are bacterial compositions useful for the treatment and / or prevention of chronic liver disease, neutropenia, and / or diseases or conditions associated with solid organ transplantation. In some aspects, the treatment and / or prevention includes the treatment of infection complications due to chronic liver disease, neutropenia, and / or solid organ transplantation. The bacterial compositions disclosed herein are designed to exhibit one or more functional profiles useful in the treatment of such diseases and disorders.

The invention relates to medicine, and more particularly to organ transplantation, and is intended to improve personalized prediction of transplant survival in the case of solid organ transplantation, using artificial intelligence. A system for the personalized prediction of transplant survival in the case of solid organ transplantation, which utilizes artificial intelligence, comprises the following, functionally interconnected via the Internet: medical institutions, recipient and transplant databases, a data-server base, and an administrative computer-programmable device with a data display monitor. The system further comprises an artificial intelligence-based predictive computer platform for solid-organ recipients which is designed to be capable of determining the best donor-recipient pairing and transplant survival on the basis of different clinical, instrumental, laboratory, histological and genetic features, and is integrated with the data-server base. The invention makes it possible to increase the functional capabilities of personalized prediction of transplant survival in the case of solid organ transplantation.

Provided herein are methods for the treatment or prevention of solid organ transplant rejection in a subject in need thereof, comprising administering to the subject a multispecific binding proteins comprising (a) a first antigen binding domain (ABD) comprising an immunoglobulin single variable domain (ISVD) (e.g., VHH) with binding specificity to CD28; and (b) a second ABD comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL) with binding specificity to OX40.

Contemplated systems and methods use high-accuracy in silico HLA analysis to so establish a transplant match database suitable for transplantation, and particularly stem cell and solid organ transplant.

To provide T cell depleting therapies.SOLUTION: The disclosure provides a method for depleting T cells for therapeutic uses, comprising administering a therapeutic anti-CD2 or anti-CD5 antibody-drug conjugate (ADC) for treatment. Provided herein are anti-CD2 ADC or anti-CD5 ADC for use as an agent to treat hematological diseases and proliferative diseases, in particular stem cell disorders, cancer or autoimmune diseases. Disclosed compositions and methods can be used to deplete cell populations of CD2+ or CD5+, including CD2+ or CD5+ cancer cells or CD2+ or CD5+ immune cells to treat hematological diseases and proliferative diseases, in particular, stem cell disorders, cancer or autoimmune diseases, and for preparing a patient to hematopoietic stem cell transplantation or solid organ transplantation.SELECTED DRAWING: None